Early versus late hormonal therapy for prostate cancer

Hiroshi Miyamoto; Edward M. Messing

doi:10.1007/s11934-004-0036-4

Early versus late hormonal therapy for prostate cancer

Hiroshi Miyamoto, Edward M. Messing

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Hormonal therapy remains the critical therapeutic option for men with advanced prostate cancer. However, considerable uncertainty remains regarding the appropriate choice/timing and actual benefits of hormonal therapy in various situations. This article reviews the relevant studies of immediate versus deferred hormonal therapy in patients with prostate cancer. The evidence from the data supports that early treatment is beneficial to many patients. Significant survival benefit of early hormonal therapy has been observed among patients with asymptomatic metastatic disease, node-positive but clinically localized disease after radical prostatectomy and lymphadenectomy, and advanced local/regional disease during and after radiotherapy.

Original language	English (US)
Pages (from-to)	188-196
Number of pages	9
Journal	Current urology reports
Volume	5
Issue number	3
DOIs	https://doi.org/10.1007/s11934-004-0036-4
State	Published - May 2004
Externally published	Yes

Keywords

Hormonal Therapy
Prostate Cancer
Radiat Oncol Biol Phys
Radiation Therapy Oncology Group
Radical Prostatectomy

ASJC Scopus subject areas

Urology

Access to Document

10.1007/s11934-004-0036-4

Cite this

@article{7d038fed7cf6411abcd1f5ec8ac737d2,

title = "Early versus late hormonal therapy for prostate cancer",

abstract = "Hormonal therapy remains the critical therapeutic option for men with advanced prostate cancer. However, considerable uncertainty remains regarding the appropriate choice/timing and actual benefits of hormonal therapy in various situations. This article reviews the relevant studies of immediate versus deferred hormonal therapy in patients with prostate cancer. The evidence from the data supports that early treatment is beneficial to many patients. Significant survival benefit of early hormonal therapy has been observed among patients with asymptomatic metastatic disease, node-positive but clinically localized disease after radical prostatectomy and lymphadenectomy, and advanced local/regional disease during and after radiotherapy.",

keywords = "Hormonal Therapy, Prostate Cancer, Radiat Oncol Biol Phys, Radiation Therapy Oncology Group, Radical Prostatectomy",

author = "Hiroshi Miyamoto and Messing, {Edward M.}",

note = "Publisher Copyright: {\textcopyright} 2004, Current Science Inc.",

year = "2004",

month = may,

doi = "10.1007/s11934-004-0036-4",

language = "English (US)",

volume = "5",

pages = "188--196",

journal = "Current urology reports",

issn = "1527-2737",

publisher = "Current Science, Inc.",

number = "3",

}

TY - JOUR

T1 - Early versus late hormonal therapy for prostate cancer

AU - Miyamoto, Hiroshi

AU - Messing, Edward M.

PY - 2004/5

Y1 - 2004/5

N2 - Hormonal therapy remains the critical therapeutic option for men with advanced prostate cancer. However, considerable uncertainty remains regarding the appropriate choice/timing and actual benefits of hormonal therapy in various situations. This article reviews the relevant studies of immediate versus deferred hormonal therapy in patients with prostate cancer. The evidence from the data supports that early treatment is beneficial to many patients. Significant survival benefit of early hormonal therapy has been observed among patients with asymptomatic metastatic disease, node-positive but clinically localized disease after radical prostatectomy and lymphadenectomy, and advanced local/regional disease during and after radiotherapy.

AB - Hormonal therapy remains the critical therapeutic option for men with advanced prostate cancer. However, considerable uncertainty remains regarding the appropriate choice/timing and actual benefits of hormonal therapy in various situations. This article reviews the relevant studies of immediate versus deferred hormonal therapy in patients with prostate cancer. The evidence from the data supports that early treatment is beneficial to many patients. Significant survival benefit of early hormonal therapy has been observed among patients with asymptomatic metastatic disease, node-positive but clinically localized disease after radical prostatectomy and lymphadenectomy, and advanced local/regional disease during and after radiotherapy.

KW - Hormonal Therapy

KW - Prostate Cancer

KW - Radiat Oncol Biol Phys

KW - Radiation Therapy Oncology Group

KW - Radical Prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=4344581118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344581118&partnerID=8YFLogxK

U2 - 10.1007/s11934-004-0036-4

DO - 10.1007/s11934-004-0036-4

M3 - Article

C2 - 15161567

AN - SCOPUS:4344581118

SN - 1527-2737

VL - 5

SP - 188

EP - 196

JO - Current urology reports

JF - Current urology reports

IS - 3

ER -

Early versus late hormonal therapy for prostate cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this